Preclinical News and Research

RSS

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

Dr Clare Scott from the Walter and Eliza Hall Institute in Melbourne, Australia, has been awarded a Victorian Cancer Agency (VCA) Clinical Fellowship to further research into an aggressive and highly lethal form of ovarian cancer.

27 Oct 2010

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

27 Oct 2010

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.

27 Oct 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen Ltd. today reported financial results for the third quarter ending September 30, 2010.

26 Oct 2010

aTyr Pharma announces $23 million Series C equity financing

aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates. Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.

26 Oct 2010

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.

26 Oct 2010

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion, Inc. a leader in regenerative medicine, presented new data on Saturday, October 23, 2010 in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL. The presentation highlighted new early data from Tengion's Neo-Kidney Augment development program demonstrating promising improvements in kidney function with an autologous cellular therapy approach to kidney regeneration in a canine model of chronic kidney disease.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies "Biosimilars" for the Treatment of Cancer.

26 Oct 2010

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Alkermes, Inc. today announced positive topline results from a phase 1 clinical study of an investigational combination of ALKS 33, one of Alkermes' proprietary candidates, and buprenorphine, an existing medication for the treatment of opioid addiction, for the treatment of cocaine addiction.

25 Oct 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy.

25 Oct 2010

Targeting c-Met protein may be effective for patients with metastatic liver cancer

A more personalized treatment for people with a type of metastatic liver cancer hepatocellular carcinoma may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers.

25 Oct 2010

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

Wright Medical launches PRO-STIM Injectable Inductive Graft

Wright Medical Group, Inc. a global orthopaedic medical device company, is pleased to announce the full commercial launch of PRO-STIM Injectable Inductive Graft.

22 Oct 2010

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases in its vaccine development efforts.

22 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-organ HCMV disease caused by multi-resistant virus. Details will be presented at the 48th IDSA meeting on October 23, presentation number LB-38.

22 Oct 2010

Preclinical News and Research

VCA Clinical Fellowship awarded for epithelial ovarian cancer research

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

aTyr Pharma announces $23 million Series C equity financing

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

NIH awards Phase I SBIR grant to develop Generic Antibodies for cancer

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Targeting c-Met protein may be effective for patients with metastatic liver cancer

Arena's NDA receives Complete Response Letter for lorcaserin

Wright Medical launches PRO-STIM Injectable Inductive Graft

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Scientists discover new cell that may limit inflammation in CNS

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics